Bristol-Myers Squibb Co. reported strong third-quarter sales of $920m for its PD-1 inhibitor Opdivo, and also a rebound for its CTLA-4 inhibitor Yervoy, but the company now has to brace for its market share to be eroded by new competition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?